Hossein Rashidi Batool, Davari Tanha Fatemeh, Rahmanpour Haleh, Ghazizadeh Mahya
Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Zanan Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Family Reprod Health. 2014 Dec;8(4):149-53.
To evaluate the impact of luteal phase support with vaginal progesterone on pregnancy rates in the intrauterine insemination (IUI) cycles, stimulated with clomiphene citrate and human menopausal gonadotropin (hMG), in sub fertile couples.
This prospective, randomized, double blind study was performed in a tertiary infertility center from March 2011 to January 2012. It consisted of 253 sub fertile couples undergoing ovarian stimulation for IUI cycles. They underwent ovarian stimulation with clomiphene citrate (100 mg) and hMG (75 IU) in preparation for the IUI cycle. Study group (n = 127) received luteal phase support in the form of vaginal progesterone (400 mg twice a day), and control group (n = 126) received placebo. Clinical pregnancy and abortion rates were assessed and compared between the two groups.
The clinical pregnancy rate was not significantly higher for supported cycles than that for the unsupported ones (15.75% vs. 12.69%, p = 0.3). The abortion rate in the patients with progesterone luteal support compared to placebo group was not statistically different (10% vs. 18.75%, p = 0.45).
It seems that luteal phase support with vaginal progesterone was not enhanced the success of IUI cycles outcomes, when clomiphene citrate and hMG were used for ovulation stimulation.
评估在使用枸橼酸氯米芬和人绝经期促性腺激素(hMG)进行促排卵的宫腔内人工授精(IUI)周期中,阴道用黄体酮进行黄体期支持对亚生育夫妇妊娠率的影响。
本前瞻性、随机、双盲研究于2011年3月至2012年1月在一家三级不孕不育中心进行。研究对象为253对接受IUI周期卵巢刺激的亚生育夫妇。他们接受枸橼酸氯米芬(100mg)和hMG(75IU)的卵巢刺激以准备IUI周期。研究组(n = 127)接受阴道用黄体酮(400mg,每日两次)形式的黄体期支持,对照组(n = 126)接受安慰剂。评估并比较两组的临床妊娠率和流产率。
接受黄体期支持的周期临床妊娠率并不显著高于未接受支持的周期(15.75%对12.69%,p = 0.3)。与安慰剂组相比,接受黄体酮黄体期支持患者的流产率无统计学差异(10%对18.75%,p = 0.45)。
当使用枸橼酸氯米芬和hMG进行排卵刺激时,阴道用黄体酮进行黄体期支持似乎并未提高IUI周期的成功率。